The development and introduction of anti-oxytocic tocolytics.
The perfect tocolytic agent, which is completely safe for both the mother and fetus and, which will inhibit uterine contractions and stop preterm labour in every case does not exist and the search continues. Recently, research into a new group of tocolytic agents (the oxytocic antagonists) has led to the introduction of a new licensed drug, atosiban. Since the early 1950s, modifications of the oxytocin molecule have resulted in many analogues and antagonists, though initially none emerged as potentially useful drugs. Further modifications resulted in full uterotonic antagonism in animal models before an analogue was found that inhibited vasopressin-stimulated uterine contractions in non-pregnant healthy women. In vitro and animal models suggested the molecule was fully antagonistic, although it was found to be only partially agonistic in women. Further developments led to two modified oxytocin molecules with higher receptor affinity for human myometrium, both of which lacked agonism in humans. The analogue, atosiban, was found to be more potent and so was chosen for clinical evaluation in dysmenorrhoea and preterm labour. The first clinical reports were open label, observational pilot studies. Randomised, double-blind, phase II placebo-controlled studies followed showing that atosiban was significantly more effective than placebo with very few side effects. Dose-response studies and phase III studies in which study or placebo groups could use alternative tocolytic agents also suggested that atosiban was an effective tocolytic agent with very few adverse events. The recent worldwide comparative study of atosiban versus different beta-agonists represents the largest and most strictly controlled study of tocolytics ever published. Atosiban was found to be at least as effective as the beta-agonists as a tocolytic agent, but significantly less likely to result in maternal cardiovascular side effects or the need to discontinue therapy as a result of unacceptable side effects.
Lamont
Ronald F
RF
Department of Obstetrics and Gynaecology, Northwick Park and St Mark's Hospitals, Harrow, UK.
D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D015195:Drug Design; D005260:Female; D006801:Humans; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D010120:Oxytocics / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015149:Tocolytic Agents / Q000737:chemistry / Q000627:therapeutic use*; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*
D010120:Oxytocics; D015149:Tocolytic Agents; C047046:atosiban; D014668:Vasotocin